NCT02199197View on ClinicalTrials.gov

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 25, 2014

Primary Completion Date

April 19, 2018

Study Completion Date

October 3, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Radium Ra 223 Dichloride

Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.

DRUG

Enzalutamide

Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02199197 - Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter